

# Phase Cancer 1 trials and building a sustainable portfolio in Wales


Rob Jones Reader and Consultant in Medical Oncology, Cardiff



# Phase 1 trials in Wales

- Provide access for Welsh patients to novel treatment options in high quality trials without needing to travel to English centres
- Provide new treatment options for patients who have exhausted conventional treatments
- Enhance reputation of Welsh Cancer Research
- Contributes to vibrant working conditions to help retain and recruit high quality staff
- Provide opportunities for translational research in collaboration with CU, UHW, Swansea and others
- Collaboration opportunities with partnership funders (VCC CF, WCRC, CRUK, CRW, CU, ECMC, Pharma)

Solid Tumour Early Phase study activity by financial year




FAKTION  
 FURVA  
 FIESTA  
 Mercuric  
 Dualides  
 Merck  
 Sanofi  
 Chk1i  
 TaxTorc  
 Drug RT






# Clinical Hours in Cycle 1



# How to futureproof Clinical Research

- Attract investment from external grant bodies (WCRC, ECMC, Velindre CF, CRW)
- Attract Pharma to run commercial trials
- Lead on new trial design by local Chief Investigators (FAKTION, FURVA, FIESTA)
- Generate research outputs in recognised Medical journals (3 in Lancet Oncology)
- Generate good collaborations locally/nationally
- Demonstrate benefit to patients

# Increasing patient visits solid tumours



Over last 3 years over 11,000 hours of patient travel saved

## Financial considerations 2014-2018

- Staff and service costs **£1,720,470**
- External grants (ECMC WCRC) £ 361,452
- Commercial trial income £1,739,587  
(including drug reimbursement)
- Net **£ 380,569**



# Challenges in futureproofing

- Fluctuations in activity through circumstances beyond our control
- Ring-fencing trial income and rolling over financial years
- Claiming drug savings from LHB's